DDrare
Disease
Drug
Target Gene/Pathway
問合せ先
EN
GM-CSF inhalation therapy ( DrugBank: - )
1 disease
告示番号
疾患名
(ページ内リンク)
臨床試験数
229
肺胞蛋白症(自己免疫性又は先天性)
1
229. 肺胞蛋白症(自己免疫性又は先天性)
臨床試験数
:
44
/
薬物数
:
22
- (
DrugBank
:
7
) /
標的遺伝子数
:
3
-
標的パスウェイ数
:
14
10
50
100
ALL
diseases per page:
Showing 1 to 1 of 1 diseases
Filter by
Reset
No.
TrialID
Date_
enrollment
Date_
registration
Public_title
Scientific_title
Condition
Intervention
Primary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
Phase
Countries
1
JPRN-JMA-IIA00205
20/07/2016
07/01/2015
Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan
Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan
autoimmune pulmonary alveolar proteinosis
Intervention type:DRUG. Intervention1:
GM-CSF inhalation therapy
, Dose form:INJECTION, Route of administration:INHALATIONAL, intended dose regimen:125mcg BID inhalation for 7days and 7days without inhalation, 12 cycles. Control intervention1:placebo controlled, Dose form:INJECTION, Route of administration:INHALATIONAL, Intended dose regimen:placebo BID inhalation for 7days and 7days without inhalation, 12 cycles.
Intervention type:DRUG. Intervention1:
GM-CSF inhalation therapy
, Dose form:INJECTION, Route of admin ...
Koh Nakata
Partner Therapeutics
Completed
>=16 YEARS
<=80 YEARS
BOTH
80
Phase 2-3
Japan